27489-62-9Relevant academic research and scientific papers
Method for recovering trans - P-aminocyclohexanol by low-concentration waste liquid
-
Paragraph 0044-0068, (2021/09/21)
The invention relates to the technical field of medical chemical raw material recycling, and particularly discloses a method for recovering trans -amino cyclohexanol from low-concentration waste liquid. The method comprises the following steps: adjusting the waste liquor to alkalinity, adding benzaldehyde and stirring, filtering and drying to obtain trans -4 - (benzylidene - amino) - cyclohexanol. The trans -4 - (benzylidene - amino) - cyclohexanol was added to a sulfuric acid solution, and after stirring, the liquid was left standing to obtain trans - p-aminocyclohexanol sulfate aqueous solution. After stirring and decoloring, the alkali content of the filtrate is adjusted to - and after the reaction is stirred, the oil layer is left to stand, and extraction, concentration and purification of the extractant are added to the oil layer to obtain trans 10 - 25% -amino cyclohexanol. To the method, waste liquid discharged in industrial synthesis of ambroxol hydrochloride and alkali waste liquid generated by trans -amino cyclohexanol can be produced, and trans -amino cyclohexanol can be recycled.
One-pot Synthesis of 4-Aminocyclohexanol Isomers by Combining a Keto Reductase and an Amine Transaminase
Sviatenko, Olha,Ríos-Lombardía, Nicolás,Morís, Francisco,González-Sabín, Javier,Venkata Manideep, Kollipara,Merdivan, Simon,Günther, Sebastian,Süss, Philipp,H?hne, Matthias
, p. 5794 - 5799 (2019/08/30)
The efficient multifunctionalization by one-pot or cascade catalytic systems has developed as an important research field, but is often challenging due to incompatibilities or cross-reactivities of the catalysts leading to side product formation. Herein we report the stereoselective preparation of cis- and trans-4-aminocyclohexanol from the potentially bio-based precursor 1,4-cyclohexanedione. We identified regio- and stereoselective enzymes catalyzing reduction and transamination of the diketone, which can be performed in a one-pot sequential or cascade mode. For this, we identified regioselective keto reductases for the selective mono reduction of the diketone to give 4-hydroxycyclohexanone. The system is modular and by choosing stereocomplementary amine transaminases, both cis- and trans-4-aminocyclohexanol were synthesized with good to excellent diastereomeric ratios. Furthermore, we identified an amine transaminase that produces cis-1,4-cyclohexanediamine with diastereomeric ratios >98 : 2. These examples highlight that the high selectivity of enzymes enable short and stereoselective cascade multifunctionalizations to generate high-value building blocks from renewable starting materials. Introduction.
A process for preparing trans to amino cyclohexanol
-
Paragraph 0020-0035, (2019/07/11)
The invention discloses a process for preparing trans to amino cyclohexanol, the method takes the aminophenol as raw material, adding metal catalyst, in order to carbonate or sulfate as an additive, in the ketone solvent in the judgement of the hydrogenation reaction to obtain the amino cyclohexanol, then post-processed to obtain trans to amino cyclohexanol. The invention uses relatively inexpensive to amino phenol, to replace the more expensive acetaminophen, the production cost is reduced, and improves the economic benefit, and exploration by the experiment, it was found that the reaction of the preparation process is relatively gentle, the reaction temperature and the reaction pressure is greatly reduced, it is easy to operate, is suitable for industrial production. Reaction of the resulting product yield can reach 80 - 90%, a high proportion of trans to amino cyclohexanol, small pollution to the environment.
ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION
-
Page/Page column 21-22, (2018/09/08)
The present invention is directed to 13C and/or 2H isotope enhanced ambroxol ("isotope enhanced ambroxol") and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drag resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced amhroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy), thus being useful against, an autophagy mediated disease state and/or condition), especially an antophagy mediated disease state and/or condition which occurs in the lungs, for example, a Mycobacterium infection. Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer (small cell and non-small cell lung cancer, among other disease states and/or conditions, especially of the lung. Methods of treating autophagy disease states and/or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention. An additional embodiment includes methods of synthesizing compounds according to the present invention as otherwise disclosed herein.
The Rhodium Catalysed Direct Conversion of Phenols to Primary Cyclohexylamines
Tomkins, Patrick,Valgaeren, Carlot,Adriaensen, Koen,Cuypers, Thomas,Vos, Dirk E. De
, p. 3689 - 3693 (2018/07/31)
Cyclohexylamines are important intermediates in chemical industry, which are currently produced from petrochemical sources. Phenols, however, are an attractive sustainable feedstock. We here demonstrate the transformation of phenols with ammonia to primary cyclohexylamines. In contrast to previously reported chemistry which used palladium catalysts, we here show that rhodium is an excellent catalyst for the formation of primary cyclohexylamines. Different parameters were studied and it was shown that the reaction is applicable to a scope of phenolic compounds providing high selectivity.
Selective Catalytic Hydrogenation of Arenols by a Well-Defined Complex of Ruthenium and Phosphorus-Nitrogen PN3-Pincer Ligand Containing a Phenanthroline Backbone
Li, Huaifeng,Wang, Yuan,Lai, Zhiping,Huang, Kuo-Wei
, p. 4446 - 4450 (2017/07/24)
Selective catalytic hydrogenation of aromatic compounds is extremely challenging using transition-metal catalysts. Hydrogenation of arenols to substituted tetrahydronaphthols or cyclohexanols has been reported only with heterogeneous catalysts. Herein, we demonstrate the selective hydrogenation of arenols to the corresponding tetrahydronaphthols or cyclohexanols catalyzed by a phenanthroline-based PN3-ruthenium pincer catalyst.
Organophosphorus-catalysed Staudinger reduction
Van Kalkeren, Henri A.,Bruins, Jorick J.,Rutjes, Floris P. J. T.,Van Delft, Floris L.
supporting information; experimental part, p. 1417 - 1421 (2012/07/03)
The first Staudinger reduction that is catalytic in phosphine has been developed, showing excellent yields and functional group selectivity. To this end we utilised dibenzophosphole catalysts and mild in situ reduction of the intermediate iminophosphoranes. We could avoid the necessity of water during the reduction, obtained no phosphine oxides as waste and thus enabled facile purification of the product. A range of azides was converted into amines with good to excellent yields and high functional group tolerance. Copyright
NEW PLEUROMUTILIN DERIVATIVE AND ITS USE
-
Page/Page column 11, (2010/11/27)
The invention is directed to the ethanedisulfonate salt of trans-4-aminocyclohexyl (lS, 2R, 3S, 4S, 6R, 7R, 8R, 14R )-4-ethenyl-3-hydroxy-2,4J7,14-tetramethyl-9- oxotricyclo[5.4.3.01,8]tetradec-6-yl imidodicarbonate (Compound IA.) Compound IA is use for the treatment of a variety of diseases and conditions, such as respiratory tract and skin an skin structure infections. Accordingly, the invention is further directed to pharmaceutical compositions comprising Compound IA. The invention is still further directed to methods of treating respiratory tract and skin and skin structure infections using Compound IA or a pharmaceutical composition comprising Compound IA.
PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S
-
Page/Page column 142, (2008/06/13)
The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group R0; (e) a group R a; (f) a group Rlb; (g) a group Rlc; (h) a group Rld; and 0) 2,6-difluorophenylamino ; wherein R )0υ, r R> llaa, T Rj I1bD, T R) I1cC, r R> Iidα, r R?2zaa, r R>22bD and RJ are as defined in the claims. The compounds have activity as inhibitors of cdk kinase (such as cdkl or cdk2) and glycogen synthase kinase-3 activity.
Selective electrochemical deprotection of cinnamyl ethers, esters, and carbamates
Hansen, Jeff,Freeman, Stanley,Hudlicky, Tomas
, p. 1575 - 1578 (2007/10/03)
Electrochemical deprotection of the cinnamyl moiety from ethers, esters, and carbamates was studied with the focus on O- versus N- selectivity as well as selectivity over allyl or benzyl systems.
